Welcome to our dedicated page for Adc Therapeutics Sa news (Ticker: ADCT), a resource for investors and traders seeking the latest updates and insights on Adc Therapeutics Sa stock.
ADC Therapeutics SA (ADCT) is a commercial-stage biopharmaceutical leader pioneering antibody drug conjugates (ADCs) for advanced oncology treatments. This page serves as the definitive source for all company announcements, including clinical trial updates, regulatory milestones, and strategic partnerships.
Investors and researchers will find curated press releases and news articles detailing ADCT's progress in developing targeted therapies for hematologic malignancies and solid tumors. Our collection includes updates on product commercialization, clinical study results, and research collaborations, providing critical insights into the company's scientific and operational trajectory.
Key content categories cover quarterly financial results, FDA/EMA regulatory filings, and advancements in ADC technology. Bookmark this page to stay informed about ADCT's innovations in precision oncology and its growing impact on cancer treatment paradigms.
ADC Therapeutics (NYSE: ADCT) reported updated LOTIS-7 Phase 1b data for ZYNLONTA plus glofitamab in r/r DLBCL showing an investigator-assessed ORR 89.8% and CR 77.6% in 49 efficacy-evaluable patients with ≥6 months follow-up.
The combination was described as generally well tolerated with notable safety findings including Grade ≥3 neutropenia in 32.7%, overall CRS 36.7% and two Grade 5 AEs (4.1%) with one deemed treatment-related. Enrollment to ~100 patients at the 150 µg/kg dose is on track for completion in 1H 2026, with full results and a manuscript planned by end of 2026.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on December 3, 2025 at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label trial. The trial evaluates safety and efficacy of ZYNLONTA combined with bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Participants can register to join by phone (toll-free 1-800-836-8184 for North America and Canada) or via a live webcast on the company's Investors "Events and Presentations" page at ir.adctherapeutics.com. The archived webcast will be available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on December 3, 2025 at 8:00 a.m. EST to provide an update on the LOTIS-7 Phase 1b open-label trial. The trial evaluates safety and efficacy of ZYNLONTA combined with bispecific antibody glofitamab (COLUMVI) in patients with relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL).
Participants can register to join by phone (toll-free 1-800-836-8184 for North America and Canada) or via a live webcast on the company's Investors "Events and Presentations" page at ir.adctherapeutics.com. The archived webcast will be available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) announced grants of options to purchase an aggregate of 47,000 common shares to two new employees on December 1, 2025 as inducements for employment. The Compensation Committee approved the grants under the company's Inducement Plan in reliance on the NYSE employment inducement exemption (Rule 303A.08).
The options vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) announced grants of options to purchase an aggregate of 47,000 common shares to two new employees on December 1, 2025 as inducements for employment. The Compensation Committee approved the grants under the company's Inducement Plan in reliance on the NYSE employment inducement exemption (Rule 303A.08).
The options vest 25% on the first anniversary and then 1/48th monthly thereafter, fully vesting on the fourth anniversary, subject to continued employment.
ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.
ADC Therapeutics (NYSE: ADCT) reported Q3 2025 results and operational updates on Nov 10, 2025. Key items: Q3 product revenue $15.8M and 9M revenue $51.2M; Q3 net loss $41.0M ($0.30/share) and 9M net loss $136.2M ($1.14/share). The company completed a $60M PIPE with estimated net proceeds of $57.6M, which would raise cash to ~$292.3M. Clinical updates: LOTIS-7 data expected by year-end 2025; LOTIS-5 topline expected in 1H 2026; Phase 2 IIT in follicular lymphoma shows ORR 98.2% and CR 83.6% with 12-month PFS 93.9% (median follow-up 28 months). IND-enabling work for PSMA ADC expected complete by end of 2025.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, November 10, 2025 at 8:30 a.m. EST to report third quarter 2025 financial results and provide operational updates.
Participants can register in advance and join the call via the North America toll-free number 1-800-836-8184. A live webcast will be available under Events and Presentations in the Investors section at ir.adctherapeutics.com. It is recommended to join 10 minutes early. The archived webcast will remain available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) will host a conference call and live webcast on Monday, November 10, 2025 at 8:30 a.m. EST to report third quarter 2025 financial results and provide operational updates.
Participants can register in advance and join the call via the North America toll-free number 1-800-836-8184. A live webcast will be available under Events and Presentations in the Investors section at ir.adctherapeutics.com. It is recommended to join 10 minutes early. The archived webcast will remain available for 30 days after the call.
ADC Therapeutics (NYSE: ADCT) will present at three investor conferences in November 2025 with CEO Ameet Mallik participating in each session.
Schedule:
- Stephens Biotechnology Virtual Fireside Chats – Nov 3, 2025 at 12:00 p.m. ET (virtual; no replay or transcript)
- Guggenheim Second Annual Healthcare Innovation Conference – Nov 11, 2025 at 1:30 p.m. ET (Boston; live webcast available)
- Jefferies Global Healthcare Conference – Nov 19, 2025 at 12:30 p.m. GMT (London; live webcast available)
Live webcasts for Guggenheim and Jefferies will be available on the company’s Events & Presentations page at ir.adctherapeutics.com, and replays will be available for approximately 30 days after each event.
FAQ
What is the current stock price of Adc Therapeutics Sa (ADCT)?
What is the market cap of Adc Therapeutics Sa (ADCT)?
